Precision AQ

Find out how satisfied HCPs are with the current digital offerings from pharma, and whether the industry has the expertise to navigate an increasingly digital/omnichannel world effectively. Plus: what HCPs and industry colleagues think AI could bring to customer engagement. Don’t miss out on this opportunity to stay ahead in the ever-evolving world of biopharma engagement. Register now for TODAY’s live #webinar at 4PM CET and submit your questions to our experts! https://lnkd.in/ezjNnW-s #OmnichannelCustomerEngagement #MarketAccess #HealthCommunications #OmnichannelTrends #PharmaIndustry #Events

?? 425+ drug launches and label expansions. That's the level of expertise Precision AQ is bringing to the table at Asembia 2025. Our team isn't just advising from the sidelines - we've been in the trenches, helping brands navigate access hurdles, payer negotiations and commercialization challenges time and time again. If you're launching a new therapy or expanding an indication, meet with us at Asembia to learn how we can help you accelerate access, avoid common pitfalls and drive real results. ?? April 27 – May 1 | Asembia 2025 ?? https://lnkd.in/eKvGtvGN #Asembia25 #AXS25 #SpecialtyPharmacy #MarketAccess #PrecisionAQ

We’re heading to Barcelona next month to exhibit at Reuters Events Pharma (9–11 April). If you’re attending, make sure to swing by our booth (no. 37). Our experts Beverly Smet, Vanessa Huichard-Tognarelli and Steeve Lamontagne will be on hand to explain how our benchmarking and other omnichannel solutions can help answer your #CustomerEngagement questions. https://lnkd.in/e-wPfe2W When booking a meeting via the online form, we would encourage you to share your therapeutic area and/or brand, to enable our experts to better tailor the session to your needs. #REpharma2025 #Events #CustomerExperience #OmnichannelTrends #CxBenchmark

The MAPS Americas Annual Meeting is off to a fantastic start! Our Medical Communications team has been thrilled to connect with current and future customers. If you're in the exhibit hall, don't miss out on a sweet, New Orleans-themed treat at booth 516 this afternoon. With a few days left at #MAPSNOLA25, we can't wait to continue creating valuable connections! #MAPsEvents #MedicalAffairs #PrecisionAQ

We’re excited to welcome Julia Wermerskirchen, PharmD, to Precision AQ’s Access Experience Team. A recognized leader in rare disease access strategy, Julia brings deep expertise in payer negotiations, reimbursement policy, and specialty pharmacy strategy—critical insights for navigating today’s evolving market. Her addition strengthens our ability to help life sciences companies proactively address access challenges and secure sustainable pathways for innovative therapies. Learn more about Julia and how she’s shaping the future of patient access: https://lnkd.in/gxg-Abfj #accessexperienceteam #marketaccess #payernegotiations #reimbursement

People caring for a family member with Alzheimer's disease or related dementias (ADRD) may experience a reduced quality of life due to physical, emotional, mental, and financial strain. We asked a group of providers and case managers which interventions would have the biggest impact on ADRD caregiver quality of life, and here are their top three choices. To learn more about the Precision AQ survey on Caregiving in ADRD, click here: https://lnkd.in/e7Tpqkpu

Ever wonder which pharma leaders are mastering the art of omnichannel engagement? Or where the industry believes AI can add value in the omnichannel space? Are you sure you’re engaging with HCPs when and how they want to be engaged? Don’t miss our live #webinar next THURSDAY (27 March) at 4PM CET and get a unique snapshot of what biopharma and its HCP and Payer audiences have been thinking and doing in the omnichannel space in 2024, as well as a look ahead at what to expect in 2025 and beyond. https://lnkd.in/ezjNnW-s #OmnichannelCustomerEngagement #MarketAccess #HealthCommunications #OmnichannelTrends #PharmaIndustry #Events

HEOR is at a crossroads—rising expectations, tighter timelines, and commercial pressures require a new approach. How can teams demonstrate their research drives real business impact? In their latest PharmaExec feature, Ross Maclean and John Graham, Pharm.D. dive into the Bookends Approach—a proven framework for aligning HEOR research with business goals without compromising scientific rigor. Learn how to apply the Bookends Approach and turn HEOR insights into action: https://lnkd.in/ecu9JEGf #HEOR #Pharma #ResearchImpact #RealWorldEvidence

Key Takeaways from #WEPA2025: What Pharma Needs to Know 1?? Affordability & Global Pricing Pressures: Governments worldwide are implementing stricter price controls, pushing for greater transparency and enforcing affordability measures. With budget constraints tightening in the US and Europe, pharma companies must rethink global pricing strategies, such as proactively exploring emerging markets like APAC and MENA. With this shift, equitable global pricing models and a clear launch market sequencing strategy to mitigate IRP challenges become imperative for a successful global launch. 2?? Rising HTA & Evidence Expectations: European HTA bodies are raising their evidence requirements for added value recognition and the impact of cross-border initiatives on evidence generation needs is unclear. APAC and MENA regions are evolving, with major pricing and reimbursement policy reforms in established markets (e.g., China, Japan) and emerging markets implementing national HTA processes (e.g., GCC, North Africa). Manufacturers must stay ahead by: ?? Adapting early to new local evidence requirements and seeking early stakeholder engagement ?? Utilizing AI-driven predictive tools to anticipate hurdles (e.g., EU JCA PICO prediction) ?? Leveraging cross-border efficiencies to streamline evidence-generation plans, approvals and pricing discussions 3?? Data-Driven Planning Is No Longer Optional: The rise of multi-indication therapies and upcoming loss of exclusivity (LOE) of multiple blockbuster drugs means that pharma companies must plan for market events earlier than ever. Analytical tools should be integrated ahead of all milestones within a product’s lifecycle to optimise launch sequencing, pricing strategy and access planning- allowing manufacturers to stay ahead of shifting market dynamics. The takeaway? Pharma companies need to think globally, act early and integrate data-driven decision-making at every step. With pricing pressures intensifying, understanding net price transparency is more critical than ever. Dive deeper into the what, how and what now of global net price transparency in our latest blog post: https://lnkd.in/e5s2nxvK #Pharma #MarketAccess #HTA #PricingStrategy

?? The AMCP 2025 Annual Meeting is in two weeks ?? Our Market Access team is packing their bags and heading to Houston for what promises to be a can’t-miss event. From strategic messaging development to engaging the right stakeholders, we’ll be sharing our industry expertise with those who want to enhance their product coverage and patient access. Book a one-on-one meeting with us between March 31st and April 3rd at and see how our team can help you. https://lnkd.in/eZjhuTUS